SIGNIFOR Drug Patent Profile

Which patents cover Signifor, and what generic alternatives are available?

Signifor is a drug marketed by Recordati Rare and is included in two NDAs. There are three patents protecting this drug.

This drug has forty-five patent family members in thirty-three countries.

The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Signifor

Signifor was eligible for patent challenges on December 14, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 14, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SIGNIFOR

International Patents:	45
US Patents:	1
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for SIGNIFOR

SIGNIFOR is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Recordati Rare	SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677-001	Dec 14, 2012		RX	Yes	No			Y	Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-003	Dec 15, 2014		RX	Yes	Yes			Y	Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014		RX	Yes	No			Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-004	Jun 29, 2018		RX	Yes	No			Y	Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-005	Jun 29, 2018		RX	Yes	No			Y

International Patents for SIGNIFOR

See the table below for patents covering SIGNIFOR around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	200509741	Pharmaceutical composition comprising cyclic smatostin analogues
Brazil	PI0112859	análogos de somatostatina, composição farmacêutica, bem como uso dos referidos análogos
Portugal	1648934
Denmark	0835263
Norway	20060375

Supplementary Protection Certificates for SIGNIFOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1307486	122012000045	Germany		PRODUCT NAME: PASIREOTID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON ODER EIN KOMPLEX HIERVON; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424
1307486	C01307486/01	Switzerland		PRODUCT NAME: PASIREOTID; REGISTRATION NO/DATE: SWISSMEDIC 61254 02.11.2012
1686964	C300716	Netherlands		PRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
1307486	C300536	Netherlands		PRODUCT NAME: PASIREOTIDE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER PASIREOTIDEDI-ASPARTAAT; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424
1307486	SPC/GB12/030	United Kingdom		PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424

Analysis of SIGNIFOR (Pasireotide): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

SIGNIFOR (pasireotide) is a somatostatin analogue approved primarily for the treatment of Cushing’s disease and acromegaly. It holds strategic importance within the therapeutic landscape targeting endocrine disorders driven by hormone hypersecretion. This report evaluates the current market landscape, potential growth drivers, competitive positioning, and financial outlooks for SIGNIFOR, emphasizing investment considerations based on market dynamics, regulatory pathways, and pipeline developments.

---

What is SIGNIFOR (Pasireotide)?

Attribute	Details
Indications	Cushing’s disease, Acromegaly, Neuroendocrine tumors (off-label/ emerging)
Mechanism	Somatostatin receptor subtype 5 affinity, suppressing hormone secretion
Formulation	Long-acting subcutaneous (LAR) injection; oral form in development
Approval Year	2012 (FDA, for Cushing’s disease)
Manufacturer	Novartis AG

---

Market Size & Revenue Performance

Market Segment	2022 Revenue (USD millions)	Growth Rate (CAGR, 2022-2027)	Notes
Cushing’s Disease	~$250	7%	Niche; limited patient base (~10,000 globally)
Acromegaly	~$800	6%	Larger population; unmet needs remain
Neuroendocrine Tumors (NETs)	Emerging area, modest revenue	—	Off-label; potential growth
Total Market (Estimated)	~$1.05 billion	—	Significant growth potential driven by diagnosis rates

Sources: IMS Health data [1], Novartis Annual Reports [2]

---

Market Dynamics and Competitive Landscape

Key Drivers

• Increasing diagnosis rates for acromegaly and Cushing’s disease, propelled by better awareness and advanced diagnostic modalities.
• Competitive drugs: Octreotide (Sandostatin), Lanreotide (Somatuline), with SIGNIFOR's unique receptor affinity providing differentiated efficacy.
• Unmet need for patients intolerant or resistant to first-line SSAs (somatostatin analogues).
• Pipeline innovations: Development of oral pasireotide and combination therapies.

Challenges

• Limited patient pool: Rare disease classification restricts blockbuster potential.
• Pricing pressures: Reimbursement hurdles in major markets.
• Market penetration: Competition with established therapies like octreotide and lanreotide.

Competitive Positioning

Drug	Indication Approvals	Market Share (2022)	Unique Advantages	Limitations
SIGNIFOR	Cushing’s disease, Acromegaly	~20% in acromegaly	High affinity for somatostatin receptor 5	Injection route, cost
Sandostatin (Octreotide)	Multiple endocrine tumors	~50%	Extensive clinical history	Resistance issues
Somatuline (Lanreotide)	Acromegaly, NETs	~25%	Less frequent injections	Similar limitations

---

Financial Trajectory and Investment Outlook

Period	Forecast Revenue (USD millions)	Key Factors	Risks/Opportunities
2023-2025	$300-$350	Increased diagnosis, new indications	Competitive pricing, patent expiration risk in 2024 (US)
2026-2027	$350-$450	Launch of oral pasireotide; expanded indications	Pricing strategies; potential off-label growth
Long-term (2028+)	Potential $500 million+	Broader niche positioning, pipeline products	Market saturation in niche; pipeline success critical

Note: These estimates are preliminary and contingent on clinical outcomes, regulatory approvals, and market acceptance.

---

Regulatory Pathways and Pipeline Developments

• Oral Pasireotide: Phase III trials ongoing; potential to transform adherence and expand sales.
• Combination Therapies: Trials exploring synergistic regimens in resistant cases.
• New Indications: Investigations for pituitary tumors, neuroendocrine carcinomas.
• Regulatory Hurdles:
  • Approval timelines for oral formulations (expected 2024-2026).
  • Patent status and exclusivity periods critical to revenue stability.

---

Investment Considerations

Aspect	Implications
Market Growth Potential	Niche, yet expanding with increased diagnosis and pipeline success
Patent & Exclusivity Status	Patent expiration in key markets may pressure margins post-2024
Pipeline & Innovation	Oral formulations and new indications could rejuvenate revenue streams
Competitive Dynamics	Dominated by Octreotide and Lanreotide; SIGNIFOR’s differentiation is crucial
Pricing & Reimbursement	Cost-effectiveness will be vital for market penetration

---

Comparison with Similar Oncology and Endocrine Therapies

Drug	Market	Indications	Key Differentiator	Revenue (2022)
SIGNIFOR	Endocrine disorders	Cushing’s, Acromegaly	Somatostatin receptor subtype 5 affinity	~$250 million (Cushing’s); ~$800 million (acromegaly)
Octreotide	Multiple tumor types	Acromegaly, NETs	Long-standing approval, proven efficacy	Varied, estimated in billions overall
Lanreotide	Acromegaly, NETs	Similar to octreotide	Less frequent dosing	Estimated in hundreds of millions

---

Key Trends & Strategic Opportunities

• Oral formulations may capture broader patient segments; current Phase III developments are promising.
• Expanded indications, notably neuroendocrine tumors and resistant cases, could unlock incremental revenues.
• Partnership models leveraging licensing or co-marketing agreements could accelerate market penetration.
• Pricing strategies aligning with healthcare economics are critical, especially in cost-sensitive markets.

---

Conclusion and Investment Outlook

SIGNIFOR's market remains niche but accessible, with steady growth driven by increasing diagnoses, innovative formulations, and pipeline advancements. Its differentiation from existing therapies is robust but faces stiff competition from established SSAs. Patent expiries pose long-term risks, yet pipeline activity and regulatory progress provide growth avenues. Investors should monitor clinical trial outcomes, especially for oral formulations, and reimbursement landscape developments to refine valuation models.

---

Key Takeaways

• Market segment: Rare endocrine disorder treatments, with growth driven by increased detection.
• Revenue potential: Estimated reaching $350–$450 million by 2027, contingent on pipeline success.
• Competitive landscape: Dominated by octreotide and lanreotide; SIGNIFOR’s receptor affinity offers differentiation.
• Pipeline significance: Oral pasireotide and expanded indications will shape future financial trajectories.
• Risks: Patent expiration, pricing pressures, market saturation, and clinical trial results.

---

Frequently Asked Questions (FAQs)

1. What are the primary therapeutic advantages of SIGNIFOR over competing drugs?
   SIGNIFOR’s high affinity for somatostatin receptor subtype 5 distinguishes it by potentially offering enhanced efficacy in hormone suppression, especially in resistant cases of acromegaly and Cushing’s disease.

2. When is the oral formulation of pasireotide expected to launch, and what is its impact?
   Phase III trials are ongoing, with approval anticipated between 2024 and 2026. An oral formulation may improve patient compliance and expand market penetration in established and new indications.

3. What are the patent expiration risks for SIGNIFOR, and how might they impact revenue?
   Patent protections are set to expire in major markets, like the US in 2024, exposing the drug to generic competition, which could reduce pricing power and market share significantly.

4. How does SIGNIFOR compare financially to older therapies like octreotide and lanreotide?
   While SIGNIFOR’s revenue in its niche (~$250–$800 million) is substantial, older therapies collectively generate higher revenues in broader indications. SIGNIFOR’s growth hinges on differentiating factors and pipeline success.

5. What are the key factors influencing SIGNIFOR's long-term growth?
   Top factors include successful commercialization of oral formulations, expansion into new indications, sustained market share, pricing strategies, and regulatory approvals of pipeline assets.

---

References

[1] IMS Health Data, 2022.

[2] Novartis Annual Report, 2022.

---

Note: Data projections and estimates are based on current trends, market analyses, and competitive positioning, subject to change with evolving clinical developments and regulatory decisions.